Overview

Effect of BMPR-2 Gene Mutations on Hemodynamic Response by Iloprost Inhalation in Pulmonary Arterial Hypertension

Status:
Completed
Trial end date:
2018-12-25
Target enrollment:
Participant gender:
Summary
In the present study, the investigators want to investigate the prevalence of BMPR-2 gene mutations in the Korean PAH patients (Step-I) and to test that the PAH patients treated with iloprost inhalation solution (Ventavis®) would show hemodynamic response, especially assessed by exercise echocardiography (Step-II).
Details
Lead Sponsor:
Gachon University Gil Medical Center
Collaborators:
Bayer
Seoul National University Bundang Hospital
Seoul National University Hospital
The Catholic University of Korea
Treatments:
Iloprost